A Phase 4 interventional study of Everolimus and Sandostatin LAR Depot in Neoplasms, sponsored by Novartis Pharmaceuticals. Completed at 24 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-11.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Study to allow access to everolimus for patients who are on everolimus treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator
This multi-center, open-label roll-over study aimed to better characterize the long-term safety of everolimus in subjects currently being treated in a Novartis-sponsored studies and who were receiving clinical benefit on the current study treatment as judged by the Investigator.
The study was designed to provide continued treatment with everolimus monotherapy to the subjects. Subjects were allowed to continue combination therapy with Sandostatin LAR® Depot if they were receiving this combination therapy on the parent protocol. Subjects were allowed to continue in this roll-over study until they no longer benefitted from the everolimus treatment as judged by the Investigator, discontinued due to toxicities, subject withdrew consent or lost to follow-up, disease progression, protocol non-compliance, or subject death, whichever occurred first. A subject was considered to have reached end of study when everolimus treatment was permanently discontinued.
As per the original protocol, it was designed to collect only serious adverse events (SAEs) and protocol defined adverse events of special interest (AESIs). However, due to the feedback received from health authorities, the protocol was amended in 2016 (3 years after study was initiated) to collect all AEs (non-serious and serious AEs, and AESIs). The protocol was also amended to include an Investigator assessment of clinical benefit at every visit for remaining subjects.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 34 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria might apply
Participants who were receiving everolimus in a Novartis-sponsored study, were not progressing on the current study treatment and were unable to access everolimus treatment outside of a clinical trial. Participants receiving everolimus treatment in combination with Sandostatin LAR Depot on the parent protocol were allowed to continue Sandostatin LAR Depot treatment.
Drug: Everolimus · Drug: Sandostatin LAR Depot
Everolimus was provided by the investigator in 2.5 mg, 5 mg or 10 mg tablets for daily oral administration. The starting dose of everolimus was the same as the last dose that was given in the parent study. Dose modification thereafter was done at the discretion of the Investigator based upon what is in the subject's best interest.
Sandostatin LAR Depot was provided by Novartis or by the investigational site considering local regulations. The dose and frequency of Sandostatin LAR Intramuscular injections was the same as the last dose that was given in the parent study.
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Any sign or symptom that occurs during the study treatment plus the 30 days post treatment. All SAEs were captured in safety database from enrollment. Safety data collection was changed in the protocol amendment released in March 2016: AEs and SAEs were captured in the clinical database from protocol amendment release (18 March 2016). Hence, SAEs from both safety database and clinical database are summarized separately.
Time frame: SAEs collected in safety database from enrollment to end of treatment (EOT) plus 30 days, up to approximately 7.2 years. AEs/SAEs collected in clinical database from protocol amendment date 18 March 2016 to EOT plus 30 days, up to approximately 4.5 years
Percentage of Patients With Clinical Benefit
Percentage of patients with clinical benefit as judged by the investigator. Investigator attestation of continued clinical benefit was collected in clinical database after protocol amendment (release date 18 March 2016). Clinical benefit assessment before protocol amendment was done retrospectively.
Time frame: After 3 months from enrollment, every 3 months, until end of treatment, assessed up to 7.2 years
There was no screening period. Patients enrolled into trial directly from the parent protocol.
| Milestone | Everolimus | Everolimus+Sandostatin LAR |
|---|---|---|
| Started | 22 | 12 |
| Completed | 0 | 2 |
| Not completed | 22 | 10 |
| Withdrew: Disease progression | 15 | 4 |
| Withdrew: Adverse event | 5 | 5 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Administrative problems | 0 | 1 |
Any sign or symptom that occurs during the study treatment plus the 30 days post treatment. All SAEs were captured in safety database from enrollment. Safety data collection was changed in the protocol amendment released in March 2016: AEs and SAEs were captured in the clinical database from protocol amendment release (18 March 2016). Hence, SAEs from both safety database and clinical database are summarized separately.
| Participants | Everolimus | Everolimus+Sandostatin LAR |
|---|---|---|
| SAEs (Safety database) | 6 | 9 |
| Treatment-related SAEs (Safety database) | 1 | 4 |
| AEs (Clinical Database) | 7 | 7 |
| Tretament-related AEs (Clinical Database) | 4 | 4 |
| SAEs (Clinical Database) | 2 | 4 |
| Treatment-related SAEs (Clinical Database) | 0 | 2 |
Percentage of patients with clinical benefit as judged by the investigator. Investigator attestation of continued clinical benefit was collected in clinical database after protocol amendment (release date 18 March 2016). Clinical benefit assessment before protocol amendment was done retrospectively.
| Participants | Everolimus | Everolimus+Sandostatin LAR |
|---|---|---|
| At 3 months | 9 | 7 |
| At 6 months | 8 | 7 |
| At 9 months | 8 | 7 |
| At 12 months | 8 | 7 |
| At 15 months | 8 | 7 |
| At 18 months | 8 | 7 |
| At 21 months | 8 | 7 |
| At 24 months | 6 | 7 |
| At 27 months | 5 | 7 |
| At 30 months | 3 | 7 |
| At 33 months | 2 | 7 |
| At 36 months | 1 | 7 |
| At 39 months | 1 | 7 |
| At 42 months | 1 | 6 |
| At 45 months | 1 | 6 |
| At 48 months | 1 | 6 |
| At 51 months | 1 | 6 |
| At 54 months | 0 | 6 |
| At 57 months | 0 | 5 |
| At 60 months | 0 | 5 |
| At 63 months | 0 | 4 |
| At 66 months | 0 | 4 |
| At 69 months | 0 | 3 |
| At 72 months | 0 | 3 |
| At 75 months | 0 | 3 |
| At 78 months | 0 | 2 |
| At 81 months | 0 | 1 |
| At 84 months | 0 | 0 |
Collected over SAEs were collected in safety database from enrollment to end of the treatment (EOT) plus 30 days, up to approximately 7.2 years. Other AEs (Non-serious AEs) were collected in clinical database from protocol amendment date 18 March 2016 to EOT plus 30 days, up to approximately 4.5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Everolimus | 1/22 (4.5%) | 6/22 (27.3%) | 3/22 (13.6%) |
| Everolimus + Sandostatin LAR | 2/12 (16.7%) | 9/12 (75%) | 5/12 (41.7%) |
| All Subjects | 3/34 (8.8%) | 15/34 (44.1%) | 8/34 (23.5%) |
| Event | Everolimus | Everolimus + Sandostatin LAR | All Subjects |
|---|---|---|---|
| PneumoniaInfections and infestations | 2/22 | 3/12 | 5/34 |
| Cardiac failure congestiveCardiac disorders | 0/22 | 2/12 | 2/34 |
| Acute kidney injuryRenal and urinary disorders | 0/22 | 2/12 | 2/34 |
| Aplastic anaemiaBlood and lymphatic system disorders | 0/22 | 1/12 | 1/34 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/22 | 1/12 | 1/34 |
| Atrial fibrillationCardiac disorders | 0/22 | 1/12 | 1/34 |
| Heart valve incompetenceCardiac disorders | 0/22 | 1/12 | 1/34 |
| Abdominal painGastrointestinal disorders | 0/22 | 1/12 | 1/34 |
| IleusGastrointestinal disorders | 0/22 | 1/12 | 1/34 |
| NauseaGastrointestinal disorders | 0/22 | 1/12 | 1/34 |
| Event | Everolimus | Everolimus + Sandostatin LAR | All Subjects |
|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/22 | 3/12 | 3/34 |
| NauseaGastrointestinal disorders | 0/22 | 2/12 | 2/34 |
| VomitingGastrointestinal disorders | 0/22 | 2/12 | 2/34 |
| Oedema peripheralGeneral disorders | 0/22 | 2/12 | 2/34 |
| Decreased appetiteMetabolism and nutrition disorders | 0/22 | 2/12 | 2/34 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/22 | 2/12 | 2/34 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/22 | 2/12 | 2/34 |
| HeadacheNervous system disorders | 0/22 | 2/12 | 2/34 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 2/22 | 0/12 | 2/34 |
| AnaemiaBlood and lymphatic system disorders | 0/22 | 1/12 | 1/34 |
| Age, Continuous(Years) | Everolimus | Everolimus+Sandostatin LAR | Total |
|---|---|---|---|
| Mean | 58.6 ± 9.52 | 57.9 ± 11.30 | 58.4 ± 10.02 |
| Sex: Female, Male(Participants) | Everolimus | Everolimus+Sandostatin LAR | Total |
|---|---|---|---|
| Female | 9 | 6 | 15 |
| Male | 13 | 6 | 19 |
| Race and Ethnicity Not Collected(Participants) | Everolimus | Everolimus+Sandostatin LAR | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.
Ran from May 2013 to primary completion in Aug 2020, 87 months.
Results were first posted in Jun 2021, 9 months after primary completion.
Of 88 phase 4 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 64. This study's 87 months is above that.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus